Key Dates

Related Announcements

NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

NOT-HL-20-782 Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform the extramural research community that NOT-HL-20-757 "Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)" will expire on May 15, 2020.

Applications will continue to be accepted for NOT-HL-20-757 on a rolling basis through May 15, 2020 by 5:00 PM local time of the applicant organization. An application submitted in response to NOT-HL-20-757 that is received on May 16, 2020 or later will be withdrawn.

Applicants who wish to propose a clinical trial may consider applying to NHLBI's Research Opportunity Announcement (ROA) OTA-20-011 "Host-targeting Therapies for COVID19" or the NOT-HL-20-782 “Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials.”

Inquiries

Please direct all inquiries to:

National Heart, Lung, and Blood Institute (NHLBI)

[email protected].